Gilead Sciences stock hits 52-week high at 121.67 USD

Gilead Sciences Inc . (NASDAQ:GILD) stock reached a 52-week high, closing at 121.67 USD. This milestone reflects a significant upward trajectory, with the stock experiencing a remarkable 70.37% increase over the past year. According to InvestingPro data, the company maintains a "GREAT" overall financial health score, with particularly strong marks in profitability and price momentum. The biopharmaceutical company has seen substantial growth, driven by its strong performance in the healthcare sector. With a market capitalization of $150 billion and an impressive 78.5% gross profit margin, Gilead has established itself as a prominent player in the biotechnology industry. This 52-week high underscores investor confidence and the company’s strategic advancements in its product pipeline, supported by its consistent dividend growth over the past decade. The stock’s impressive performance over the year highlights its resilience and potential for continued growth in the competitive biotech industry. With analyst targets reaching as high as $143, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Gilead Sciences reported robust second-quarter earnings, with total sales reaching $7.1 billion and earnings per share of $1.97. This performance led several analyst firms to adjust their price targets for the company. BofA Securities raised its price target to $140, maintaining a Buy rating, while RBC Capital increased its target to $98, keeping a Sector Perform rating. TD Cowen also adjusted its target to $115, highlighting a 3% earnings per share beat primarily driven by strong HIV sales. Morgan Stanley (NYSE:MS) set a new price target of $143, citing the company’s strength in the HIV segment, which contributed to revenue of $7.08 billion. Truist Securities upgraded Gilead to a Buy rating, raising its price target to $127, following the company’s second-quarter outperformance and subsequent increase in full-year guidance. The focus on Gilead’s HIV business appears to be a common theme among analysts, as the company exceeded expectations in this area. These developments reflect the company’s current standing and potential future growth, according to the analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.